ReviewHepatic oncology2016
Dysregulated fatty acid metabolism in hepatocellular carcinoma.
Review in Hepatic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 96 citations in OpenAlex.
- Lipid Metabolism-related lncRNA Model IdentifiesJournal of clinical and translational hepatology · 2026Article
- Functional Role of COP1 Gene in Hepatocellular Carcinoma Lipid Metabolism and Stemness.Genes to cells : devoted to molecular & cellular mechanisms · 2026Article
- The efferocytosis-related genes of SLC26A6, TYRO3, and PDK4 have been identified as predictors of prognosis in hepatocellular carcinoma and are associated with the immune status.International journal of medical sciences · 2026Article
- Metabolites involvement in the growth and spread of liver cancer.Liver research (Beijing, China) · 2025Review
- Differential Metabolic Dysregulations in Hepatocellular Carcinoma and Cirrhosis: Insights into Lipidomic Signatures.Biomolecules · 2025Article
- Association of TP53 with Defective Long Chain 3-Hydroxy acyl-CoA Dehydrogenase Induced Non-Cirrhotic Hepatocellular Carcinoma.Cancers · 2025Article
- SPP1 promotes malignant characteristics and drug resistance in hepatocellular carcinoma by activating fatty acid metabolic pathway.Functional & integrative genomics · 2025Article
- From genes to therapy: a lipid Metabolism-Related genetic risk model predicts HCC outcomes and enhances immunotherapy.BMC cancer · 2025Article
- Exploring non-coding RNA expression profiles of AKR1B10P1, RP11-465B22.3, WASH8P, and NPM1P25 as a predictive model for hepatocellular carcinoma patient survival.Discover oncology · 2025Article
- Nuclear magnetic resonance-based lipid metabolite profiles for differentiation of patients with liver cirrhosis with and without hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2025Article
- Exploring lipidomic profiles and their correlation with hormone receptor and HER2 status in breast cancer.Oncology letters · 2025Article
- MicroRNA-372-3p impairs fatty acid metabolism in hepatocellular carcinoma cells by targetingBioImpacts : BI · 2025Article
- SPP1+ tumor-associated macrophages define a high-risk subgroup and inform personalized therapy in hepatocellular carcinoma.Frontiers in oncology · 2025Article
- Zbtb7b defines a compensatory mechanism in MASLD-related HCC progression by suppressing H19-mediated hepatic lipid deposition.Physiological reports · 2024Article
- Investigating the diagnostic and prognostic significance of genes related to fatty acid metabolism in hepatocellular carcinoma.BMC gastroenterology · 2024Article
- Article
- Acyl-CoA Synthetase Medium-Chain Family Member 5-Mediated Fatty Acid Metabolism Dysregulation Promotes the Progression of Hepatocellular Carcinoma.The American journal of pathology · 2024Article
- TRIM65/NF2/YAP1 Signaling Coordinately Orchestrates Metabolic and Immune Advantages in Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- SNHG1: Redefining the Landscape of Hepatocellular Carcinoma through Long Noncoding RNAs.Biomedicines · 2024Review
- Regulation and targeting of SREBP-1 in hepatocellular carcinoma.Cancer metastasis reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most frequent and deadly malignancies worldwide. Studies are urgently needed on its molecular pathogenesis and biological characteristics. Dysregulation of fatty acid (FA) metabolism, in which aberrant activation of oncogenic signaling pathways alters the expression and activity of lipid-metabolizing enzymes, is an emerging hallmark of cancer cells, and it may be involved in HCC development and progression. The current review summarizes what is known about dysregulated FA metabolism in HCC and pathways through which this dysregulation may regulate HCC survival and growth. Our understanding of dysregulated FA metabolism and associated signaling pathways may contribute to the development of novel and efficient antitumor approaches for patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.